

April 27, 2016

MockV Solutions Announces Presentation of its Mock Virus Particle Technology Program at the 2016 Cambridge Health Institute BioProcessing Summit

Rockville, MD – April 27, 2016 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it has been invited to present preliminary results from proof of concept studies of its lead product, the MVM_{MVP} Kit, at Cambridge Health Institute's (CHI) annual BioProcess Summit on August 15 - 19, 2016 in Boston, MA.

A poster displaying the results will be available for viewing throughout the conference and an oral presentation will be given by MockV CEO – David Cetlin – on Friday, August 19, 2016 at 9:30 am in the Virus and Pathogen Clearance and Safety in Biologics track. The presentation and poster will introduce the concept of utilizing Mock Virus Particle (MVP) technology for predicting live Minute Virus of Mice (MVM) clearance results during downstream bioprocess development and will outline results from an anion exchange and virus filtration spiking study.

Poster and Oral Presentation Titles:

- *Characterization and Use of a Mock Virus Particle as Spiking Surrogates for Downstream Process Development Studies*

About CHI's BioProcessing Summit

The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line selection to bioproduction. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking. This leading bioprocess meeting is hosted in Boston each summer along the lively and cosmopolitan harbor waterfront. Each year, the international bioprocessing community comes together at the Summit to share practical solutions for today's bioprocess challenges with researchers from around the world. Spanning five days, the 2016 meeting includes 16 conference programs, 9 training seminars, and 10 short courses. More details about the conference can be found at <http://www.giiconference.com/chi351314/>

About MockV Solutions Inc.

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically

challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactivate virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging “spiking studies”. The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements - jeopardizing the timely approval of potentially life-altering therapies. MockV’s lead product candidate, the MVM_{MVP} Kit contains a non-infectious “Mock Virus Particle” (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution. Currently, this business segment is supported by a \$100,000 convertible note from the Technology Commercialization Fund of The Maryland Technology Development Corporation (TEDCO)

For further information regarding MockV Solutions, Inc., please visit the Company’s website at www.mockvsolutions.com.